Dataset Information


Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.

ABSTRACT: BACKGROUND:To evaluate the effect of upadacitinib on patient-reported outcomes (PROs) in patients with RA who had an inadequate response to csDMARDs. METHODS:Patients in SELECT-NEXT, a randomised controlled trial, were on a background of csDMARDs and received upadacitinib 15?mg and 30?mg or placebo daily for 12?weeks. PROs included Patient Global Assessment of Disease Activity (PtGA), pain, Health Assessment Questionnaire-Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), duration and severity of morning (AM) joint stiffness, Short Form 36 Health Survey (SF-36), and Work Instability Scale for RA (RA-WIS). Least squares mean (LSM) changes were based on mixed-effect repeated measure models. Percentages of patients reporting improvements ? minimum clinically important differences (MCIDs) and scores ? normative values and number needed to treat (NNT) were determined; group comparisons used chi-square tests. RESULTS:Data from 661 patients were analysed. Compared with placebo, patients receiving upadacitinib reported statistically significant improvements (both doses, P?


PROVIDER: S-EPMC6902348 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6889334 | BioStudies
2017-01-01 | S-EPMC5413813 | BioStudies
2017-01-01 | S-EPMC5353328 | BioStudies
2018-01-01 | S-EPMC6009058 | BioStudies
2017-01-01 | S-EPMC5372156 | BioStudies
2016-01-01 | S-EPMC5051508 | BioStudies
2017-01-01 | S-EPMC5705852 | BioStudies
2017-01-01 | S-EPMC5604362 | BioStudies
2017-01-01 | S-EPMC5604726 | BioStudies
2016-01-01 | S-EPMC5012017 | BioStudies